July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Development of Biocompatible Photosensitizing Nanocomplex for Photodynamic Therapy Against Retinoblastoma After Intravitreous Injection
Author Affiliations & Notes
  • Dong Hyun Jo
    Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, Korea (the Republic of)
    Tumor Microenvironment Research Center, Global Core Research Center, Seoul National University, Seoul, Korea (the Republic of)
  • Keunsoo Jeong
    Center for Theragnosis, Korea Institute of Science and Technology, Seoul, Korea (the Republic of)
  • Jin Hyoung Kim
    Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, Korea (the Republic of)
    Tumor Microenvironment Research Center, Global Core Research Center, Seoul National University, Seoul, Korea (the Republic of)
  • Jeong-Hwan Che
    Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • WonHyoung Ryu
    Department of Mechanical Engineering, Yonsei University, Seoul, Korea (the Republic of)
  • Noo Li Jeon
    School of Mechanical and Aerospace Engineering, Seoul National University, Seoul, Korea (the Democratic People's Republic of)
  • Sehoon Kim
    Center for Theragnosis, Korea Institute of Science and Technology, Seoul, Korea (the Republic of)
  • Jeong Hun Kim
    Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, Korea (the Republic of)
    Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Dong Hyun Jo, None; Keunsoo Jeong, None; Jin Hyoung Kim, None; Jeong-Hwan Che, None; WonHyoung Ryu, None; Noo Li Jeon, None; Sehoon Kim, None; Jeong Hun Kim, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1635. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dong Hyun Jo, Keunsoo Jeong, Jin Hyoung Kim, Jeong-Hwan Che, WonHyoung Ryu, Noo Li Jeon, Sehoon Kim, Jeong Hun Kim; Development of Biocompatible Photosensitizing Nanocomplex for Photodynamic Therapy Against Retinoblastoma After Intravitreous Injection. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1635.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the therapeutic potential of the biocompatible photosensitizing nanocomplex for photodynamic therapy against retinoblastoma after intravitreous injection.

Methods : The degree of diffusion of the nanocomplex was evaluated in phosphate-buffered saline and porcine vitreous. Fluorescence-activated cell sorting and immunofluorescence analyses provided the data on the degree of endocytosis of the nanocomplex into retinoblastoma cells, Y79, WERI-Rb1, and SNUOT-Rb1. The cytotoxic potential of the nanocomplex was estimated using cell viability assays after the treatment of the nanocomplex and the following laser irradiation. Two weeks after the injection of retinoblastoma cells into the vitreous cavity of Balb/c nude mice to form orthotopic transplantation models, the degree of in vivo endocytosis of the nanocomplex was evaluated by the observation of tumor sections under a fluorescence microscope. The same orthotopic transplantation models were also employed to demonstrate in vivo therapeutic efficacy of the photodynamic therapy after intravitreous injection of the nanocomplex.

Results : The photosensitizing nanocomplex was formed with self-assembly of a photosensitizer and a biocompatible surfactant. In contrast to free methylene blue, which poorly penetrates to tumor cells, the nanocomplexed methylene blue demonstrated effective penetration to retinoblastoma cells. Also, further laser irradiation induced cytotoxicity of retinoblastoma cells after treatment with the nanocomplexed methylene blue. In vivo experiments using an orthotopic transplantation mouse model showed that this photosensitizing nanocomplex penetrated well-formed in vivo tumors after intravitreous injection. Furthermore, photodynamic therapy based on this nanocomplex decreased the degree of tumor formation in the vitreous of mice.

Conclusions : We expect that this photosensitizing nanocomplex based on biocompatible materials can expand the use of photosensitizing materials and photodynamic therapy in the treatment of retinoblastoma.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Diffusion of the photosensitizing nanocomplex in phosphate-buffered saline (PBS) and porcine vitreous. min, minute(s); h, hour(s).

Diffusion of the photosensitizing nanocomplex in phosphate-buffered saline (PBS) and porcine vitreous. min, minute(s); h, hour(s).

 

Therapeutic efficacy of the photodynamic therapy using the photosensitizing nanocomplex on in vivo tumor formation in orthotopic transplantation models of retinoblastoma.

Therapeutic efficacy of the photodynamic therapy using the photosensitizing nanocomplex on in vivo tumor formation in orthotopic transplantation models of retinoblastoma.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×